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Abstract
Background: Cystic echinococcosis (CE) constitutes an important public health problem in Peru. However, no studies have
attempted to estimate the monetary and non-monetary impact of CE in Peruvian society.
Methods: We used official and published sources of epidemiological and economic information to estimate direct and
indirect costs associated with livestock production losses and human disease in addition to surgical CE-associated disability
adjusted life years (DALYs) lost.
Findings: The total estimated cost of human CE in Peru was U.S.$2,420,348 (95% CI:1,118,384–4,812,722) per year. Total
estimated livestock-associated costs due to CE ranged from U.S.$196,681 (95% CI:141,641–251,629) if only direct losses (i.e.,
cattle and sheep liver destruction) were taken into consideration to U.S.$3,846,754 (95% CI:2,676,181–4,911,383) if additional
production losses (liver condemnation, decreased carcass weight, wool losses, decreased milk production) were accounted
for. An estimated 1,139 (95% CI: 861–1,489) DALYs were also lost due to surgical cases of CE.
Conclusions: This preliminary and conservative assessment of the socio-economic impact of CE on Peru, which is based
largely on official sources of information, very likely underestimates the true extent of the problem. Nevertheless, these
estimates illustrate the negative economic impact of CE in Peru.
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Introduction
Cystic echinococcosis (CE) is caused by infection with the larval
stage of the cestode Echinococcus granulosus. CE has a cosmopolitan
distribution and is an important public health problem in sheep-
raising areas of South America [1]. CE has a serious impact on
human health and livestock production in Peru as demonstrated by
epidemiological studies in endemic villages of Peru that have shown
human infection prevalences ranging from 5.5% to 9.1% (see
Table 1) [2,3], with the prevalence of CE in sheep and cattle as high
as 77% and 68%, respectively [2,4]. Despite these levels of infection,
CE is not a notifiable disease in Peru. CE not only causes disability
and occasional death in humans, but also results in monetary losses
due to treatment costs, lost wages, and animal productivity losses.
An economic analysis of the losses due to CE in Uruguay revealed
an estimated minimum cost of U.S.$ 2.9 million per year in losses in
livestock productivity together with the cost of hospital treatment of
human cases [5]. Despite the high levels of CE in Peru, no study has
explored the socioeconomic or financial impact of this disease in
Peru. Studies to estimate the economic impact of CE are important
as they can serve as tools to help prioritize those areas that may need
to be targeted in a control program.
Disability-adjusted life years (DALYs) have been used to
quantify disease burden for a wide range of afflictions globally,
and it was the primary metric used in the Global Burden of
Disease (GBD) Study [6,7]. DALYs offer a standardized, non-
monetary measure of morbidity and mortality that is comparable
across various conditions and geographic regions. The DALY also
serves as a useful tool for resource allocation and cost-effectiveness
analyses. Calculation of DALYs involves summing the years of life
lost due to premature mortality and the years of a healthy life lost
due to the disability caused by the infection in a specific
population, accounting for the degree of incapacity resulting from
various conditions (disability weights) and the relative importance
of a healthy life at different ages (age-weights). DALYs have
previously been applied to assess the economic impact of CE on a
regional and global scale [8,9]. Given the absence of data on this
subject, this study was designed to provide a preliminary estimate
of the socio-economic impact of CE in Peru.
Materials and Methods
Human CE epidemiological parameters
Data on annual reported cases of CE, by age, gender, and by
cyst location (Table 2), were obtained from official government
and published sources [10–12; Ministry of Health of Peru,
unpublished data]. Government agencies in Peru record the
number of new CE cases seen in outpatient clinics in public
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healthcare facilities, but no information is currently collected by
the government on the number of CE cases that undergo surgical
treatment. In order to estimate the number of cases of CE
that underwent surgery nationally, we applied the proportion of
CE cases who underwent surgical treatment from a known
endemic area (for which data is available) [12] to the number
of CE cases seen in outpatient clinics nationally. Thus, it was
assumed that the proportion of CE cases who undergo surgery in
this endemic region would also apply to the entire country
(Table 2).
Community-based data are not available to determine the
proportion of asymptomatic or non-healthcare seeking CE
patients in the Peruvian population. Therefore, the ratio of cases
detected via abdominal ultrasound screening in a community
survey to surgical incidence cases determined for the Junin
Department was used to estimate the number of asymptomatic
cases in Peru [2]. In this study, the ultrasound-based CE
prevalence was 5.7%, with a surgical incidence of 127 cases per
105 person years, resulting in a ratio of 44.9. When this ratio was
applied to the countrywide Peruvian data, with an estimated
surgical incidence of 3.6 cases per 105 person years, the prevalence
of undiagnosed cases was estimated to be 0.162%. Due to the
uncertainty associated with this estimate, a triangular distribution
with a minimum of 0%, a maximum of 0.2%, and a most likely
value of 0.163% was used. The proportion of cases with post-
surgical mortality was obtained from the literature, which
suggested that approximately 1.9% of surgical cases in Peru die
post-operatively (11).
A reduction in productivity was modeled for all healthcare
seeking CE cases (surgical and outpatient) and non-healthcare
seeking cases. Due to scarcity of data on productivity reduction
associated with CE, an estimated 2% reduction, with a uniform
distribution of 0% to 4%, was utilized based on the only available
data [13]. Fatal cases were assigned a 100% loss of productivity.
We did not estimate costs associated with non-surgical treatment
of CE (other than PAIR which is not available in Peru) as we are
not aware of any local or international publication that has
assessed this form of treatment.
Economic evaluation of human CE-associated losses
Mean overall costs per human surgical CE case, by cyst location
(e.g., hepatic, pulmonary, or both), were obtained from published
sources [14]. The cost of a surgical hepatic CE case was estimated
at U.S.$645, the cost of a surgical pulmonary CE case was
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estimate direct and indirect costs associated with livestock
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found that the total estimated cost of human CE in Peru
was U.S.$2,420,348 per year. Total estimated livestock-
associated costs due to CE ranged from U.S.$196,681 to
U.S.$3,846,754. An estimated 1,139 DALYs were also lost
due to surgical cases of CE which is comparable to DALY
losses from Amebiasis or Malaria in Peru. This conservative
assessment found significant economic losses caused by
this CE in Peruvian society. The findings of this study are
important as these data can serve to prioritize those areas
that may need to be targeted in a control program.
Table 1. Human incidence and prevalence of cystic
echinococcosis in Peru.
Parameter Reference
Peru
Surgical incidence 1–2{ 2,26
3–4{ Current study
Regionally (Departments)
Lima
Vichaycocha 9.3%{ 3
Junı´n
Overall surgical incidence 11.7 { 12
Rural farming area (SAIS Tupac Amaru) 5.4%{ 2
Pasco 5.5%{ 28
Ica – Chincha 32{ 23
{Cases per 100,000 inhabitants
{Ultrasound and chest-X-ray survey
doi:10.1371/journal.pntd.0001179.t001
Table 2. Epidemiological parameters used to estimate the
monetary and non-monetary burden of human CE in Peru,
2007.
Category Value Distribution Ref.
Population of Peru 26,152,265 Fixed 27
Annual surgical incidence of CE
(cases per 100,000)
3–4 Uniform 12,22
New CE outpatients 2189 Fixed 22
Asymptomatic or non-healthcare
seeking cases
0–0.015–0.02 Triangular See
text
Gross national income
(US $ per capita)
3,450 Fixed 9
Mortality (% of surgical cases) 1.9% Log Normal 11
Location of CE cysts: 11
Liver 44.9% Fixed
Lung 32.5% Fixed
Liver and lung 22.6% Fixed
Distribution of CE by age (in years): 22
0–9 7.6% Fixed
10–19 19.2% Fixed
20–39 34.9% Fixed
40–49 12.1% Fixed
50–59 9.5% Fixed
60+ 16.7% Fixed
Distribution of CE by sex: 22
Male 43.3 Fixed
Female 56.7 Fixed
doi:10.1371/journal.pntd.0001179.t002
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estimated at U.S.$831, and the cost of a surgical case of hepatic
and pulmonary CE was estimated at U.S.$ 1,476. Cost per
surgical patient included costs associated with the surgical
procedure itself along with the cost of diagnostic testing,
medications, and hospitalization. Per capita GNI (U.S.$3,450)
for 2007 was used as the economic contribution of each affected
patient and was, therefore, used to estimate productivity losses
[15].
Livestock CE epidemiological parameters
The prevalence of CE in livestock was calculated from official
government abattoir data (Table 3) [10]. Reduction in livestock
productivity, due to CE, has been documented by others and was
assumed to occur in Peru [16]. Production-based losses attribut-
able to infected cattle, sheep, goats, pigs, alpacas and llamas were,
therefore, estimated based on previous reports [5] (Table 4).
Economic evaluation of livestock CE-associated losses
Current market value for livers, meat, wool, and milk were
obtained from official sources (Table 4) [17]. However, the price of
a sheep liver was not available. Therefore, the maximum cost of a
sheep liver was assumed to be proportional to the cost of cattle
liver based on the proportion found in a previous study conducted
in Tunisia where cattle liver was found to be 1.8 times more
valuable than sheep liver [18]. Due to uncertainty, a uniform
distribution with a minimum of no economic losses per infected
sheep liver to a maximum of U.S.$1.94 per infected sheep liver
was modeled. Losses from liver condemnation, defined as the
action of preventing the sale of livers deemed unfit for human
consumption (cattle and sheep), meat production losses (all
species), decrease in wool value (sheep, alpacas, llamas), and
decreased milk production (cattle) were calculated using produc-
tion losses caused by CE as previously described [5,16] (Table 4).
Application of DALYs to human surgical CE cases
The DALY formula was applied to age and gender stratified
human CE surgical incidence data. The DALY is made up of two
parts; years of life lost due to mortality (YLL) and years of life lost
due to time lived in a disability state (YLD). The formulas for YLL
and YLD are:
YLL~ N  L
where N = number of deaths per age-sex group, L = remaining
life expectancy at age of death
YLD~ I  DW  D
where I = age and sex specific estimates of incidence, DW =
disability weight, D = average duration of disability.
Disability weight for CE was assigned a multinomial distribution
based on numerous retrospective studies evaluating postoperative
outcome. In accordance with previous studies, the percentage of
patients projected to improve after surgery was assigned a
disability weight of 0.200 for 1 year, the percentage of patients
projected to have substantial postsurgical complications was
assigned a disability of 0.239 for 5 years, the percentage of
patients projected to have recurrent disease was assigned a
disability of 0.809 for 5 years, and the percentage of patients
projected to die postoperatively were assigned a disability of 1
(indicating death) for the remainder of their predicted lifespan [7].
Since malignant neoplasms of the respiratory tract (the best
surrogate for CE of the lungs) have a similar disability weight at
diagnosis (0.150) to that used previously for hepatic CE (0.200) and
the same disability weights for sequelae, CE cases were assigned
the same spectrum of disability weights regardless of lesion site.
This also allows for estimates from this study to be comparable to
previously published estimates for CE burden.
Analysis
Spreadsheet models were constructed in Excel (Microsoft,
Redmond, WA) utilizing the @Risk (Palisade Corp., Ithaca, NY)
statistical add-in. Values were selected across the various assigned
distributions and summed using Latin Hypercube sampling
techniques. A total of 10,000 simulations were performed and
the mean and 95% confidence intervals (CI) obtained for annual
losses. Step-wise linear regression of the estimated CE-associated
costs against the input parameters was conducted to assess the
impact of individual parameters on the overall cost estimate.
This study was exempted from human subjects review by the
Institutional Review Board of the Centers for Disease Control and
Prevention because no personal identifiers were collected.
Results
Human health costs
Human health costs resulting from CE can be observed in table 5.
Direct costs associated with surgical treatment of CE were estimated
to account for U.S.$ 836,064 (95% CI:731,271–948,236) per year.
Human health costs resulting from lost productivity were estimated
at U.S.$1,592,764 (95% CI:310,664–3,947,315) annually. The total
estimated cost of human surgical CE cases and productivity losses
from non-surgically treated cases in Peru was estimated at U.S.$
2,420,348 (95% CI:1,118,384–4,812,722) per year.
Animal health costs
The estimated losses resulting from liver condemnation and
production losses in each animal species are detailed in table 6.
Total estimated losses due to CE ranged from U.S.$196,681 (95%
CI:141,641–251,629) if only direct losses (i.e., cattle and sheep
liver losses) are taken into consideration to U.S.$3,846,754 (95%
CI:2,676,181–4,911,383) if all production losses evaluated (liver
losses, decreased carcass weight, wool losses, decreased milk
production) are accounted for.
Disability adjusted life years (DALYs)
The estimated number of DALYs lost due to surgical CE in Peru
was estimated at 1,139 (95% CI: 861–1,489). Table 7 shows DALYs
Table 3. Prevalence of CE at slaughter.
Livestock
species
Prevalence of cysts at abattoir
inspection (national level)* Distribution
Sheep 10% Fixed
Goats 5.5% Fixed
Cattle 6.0% Fixed
Alpaca 2.0%–9.0% Uniform
Llama 2.0%–9.0% Uniform
Swine 3.8% Fixed
*Ref 10
doi:10.1371/journal.pntd.0001179.t003
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lost for surgical cases of CE in comparison with other infectious
diseases in Peru as well as estimated DALYs lost due to CE in other
South American countries (Argentina, Brazil, Chile and Uruguay).
Sensitivity analysis
Sensitivity analysis for monetary losses associated with CE,
indicated that human productivity losses (0.691), the estimated
number of sub-clinical cases (0.447), losses due to decreased cattle
carcass weight (0.339), and losses due to decreased milk production
in cattle (0.281) had the largest coefficient values (in brackets) and,
therefore, the greatest impact on the overall estimate on monetary
losses due to CE in Peru.
Discussion
This is the first study to provide an assessment of the economic
effects of CE in humans and livestock in Peru. Studies that estimate
the economic burden of CE can be very important as they identify
specific areas that may need to be addressed by policy makers
responsible for the design and implementation of CE control
programs. The economic impact of CE has been assessed in South
American countries where CE is endemic [5,19]. A recent study in
Argentina, Brazil, Chile and Uruguay demonstrated total adjusted
human and animal losses of US $ 108,276,378-$ 146,580,935 for all
four countries combined [19]. However, it is difficult to make direct
comparisons with other countries due to demographic and
epidemiological differences. In addition, there is no standard
approach recognized when estimating economic costs for CE in
human and animal populations. For example, treatment costs for
non-surgical CE patients were not estimated and included in the
present study. Per capita GNI was also used in this study to account
for human productivity losses rather than taking into account
income losses for those who work outside the home versus those who
are not officially employed. In addition, losses due to decreased
fecundity were not included due to the lack of information on the
true impact of CE on reproduction. In addition, livestock were not
separated by age since CE prevalence data is not available for
different age groups of domestic livestock. Finally, farmer
investment was also not taken into consideration. In the present
study, total estimated losses due to CE were U.S. $ 6,357,027 (95%
Table 4. Parameters used to estimate monetary losses due to CE in livestock, Peru 2007.
Livestock product Current market value* Annual production (kgs) Production losses (%) b Distribution
Liver:
Cattle $2.40/liver ___ 100 Fixed
Sheepa $0–$1.94/liver ___ 100 Fixed
Meat
Cattle $2.21/kg 163,235,000 2.5–10 Uniform
Sheep $2.50/kg 33,979,000 2.5–10 Uniform
Goat $2.50/kg 6,721,000 2.5–10 Uniform
Pig $2.22/kg 114,740,000 2.5–10 Uniform
Alpaca $2.50/kg 9,400,000 2.5–10 Uniform
Llama $2.50/kg 4,056,000 2.5–10 Uniform
Wool*
Sheep $12,420,444 10,885,000 10–20 Uniform
Alpaca $11,224,825 3,881,000 10–20 Uniform
Llama $1,030,423 724,000 10–20 Uniform
Cows’ milk $0.28/kg 1,575,277,00 0–5 Uniform
*Current market value in terms of total annual production in Peru, ref 17
aRef 18
bRef 16
doi:10.1371/journal.pntd.0001179.t004
Table 5. Costs associated with human cystic echinococcosis
in Peru.
Category of loss
Median
(in U.S.$)
95% CI
(in U.S.$)
Surgical cases of hepatic CE 191,223 167,254–216,878
Surgical cases of pulmonary CE 340,487 297,810–386,169
Surgical cases of hepatic/pulmonary CE 304,354 266,206–345,188
Mortality-associated productivity losses 45,343 37,187–55,875
Productivity losses (surgical cases) 47,563 4,357–91,422
Productivity losses (outpatients) 115,704 12,031–218,097
Productivity losses (asymptomatic cases) 1,370,468 121,685–3,747,867
Total losses 2,420,348 1,118,384–4,812,722
doi:10.1371/journal.pntd.0001179.t005
Table 6. Livestock-associated economic losses due to cystic
echinococcosis in Peru.
Category of loss Median (in U.S.$) 95% CI (in U.S.$)
Direct losses (liver losses) 196,681 141,641–251,629
Meat production losses 2,675,475 1,777,403–3,532,182
Wool production losses 287,541 203,345–380,944
Milk production losses 655,472 62,955–1,267,465
Total losses 3,846,754 2,676,181–4,911,383
doi:10.1371/journal.pntd.0001179.t006
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CI: 4,422,699–8,788,182) of which two-thirds comprised human
economic losses and the other third were animal production losses.
This is a very conservative estimate based to a large extent on official
sources of information which very likely underestimate the true
extent of the problem. Nevertheless these estimates illustrate the
negative economic impact of CE in Peru.
In Peru, surgery remains the treatment of choice for CE.
Surgical treatment of CE is a costlier alternative than the less
invasive puncture-aspiration-injection-reaspiration (PAIR) tech-
nique or benzimidazole use. In Argentina, a country where CE is
endemic, the average cost of conventional surgery for CE of the
liver was $5,936 in comparison to the cost of PAIR at $1,988 and
$1,350 for albendazole treatment [20]. PAIR is not available in
Peru and use of benzimidazoles is reserved for prophylactic use
prior to surgery [21]. Use of less costlier procedures in Peru such
as PAIR and sole chemotherapeutic treatment could result in
lower overall treatment costs. Our estimate of the cost of surgical
treatment for CE is based on the cost incurred in a public hospital
located in Lima city. Costs may vary in other areas of Peru,
especially in endemic areas. Therefore, our estimates may not
reflect the true cost of surgical treatment in the country. In
addition, this estimate does not take into account an important
number of patients who receive treatment at private clinics where
the cost of surgical treatment can be 4 or more times higher than
in public hospitals. In one study in an endemic area of Peru, 8% of
patients received treatment in private clinics compared to 44% in
public hospitals and 47% in hospitals of the national health care
system [12]. Our estimates of treatment costs for CE underesti-
mates the true cost of human CE as we did not include the cost of
benzimidazoles given the absence of data on sole benzimidazole
use against CE in Peru.
An important limitation of this study is the absence of current
data on the incidence or prevalence of CE in humans and animals.
Available sources of data have not been updated for the last 20–30
years. Although the Peruvian Ministry of Health has regularly
collected information on outpatient consultations due to CE since
2000, it is not known how many of these cases were confirmed and
the type of treatment received. Data on CE condemned livestock
viscera at the national level is collected by the Peruvian Ministry of
Agriculture from inspections performed in abattoirs. However, a
substantial number of livestock are home slaughtered, particularly
in areas endemic for CE. In addition, younger animals, which are
less likely to be infected, tend to be slaughtered in abattoirs.
Therefore, these official sources of information may greatly
underestimate the real prevalence of infection. For example,
based on official publications, the incidence of human CE in the
endemic Department of Junin was 24 cases per 100,000 during
2002 [22]. However, epidemiological studies conducted in Junin
have demonstrated that the surgical incidence can reach 127 cases
per 100,000 [2]. Similarly, official records showed that in the
coastal city of Chincha the incidence of human infection was 10
cases per 100,000 during 2005 [22], but an epidemiological
investigation revealed a surgical incidence of 32 cases per 100,000
population [23]. For livestock, official sources indicated a
prevalence of sheep CE of 10% for 2002 in the Department of
Junin [10]. However, epidemiological studies in abattoirs in this
same area showed that as many as 77% of sheep were infected [4].
We estimated that 1,139 (95% CI: 861–1,489) DALYs are lost
annually in Peru due to surgical cases of CE, which is comparable
to CE-associated DALYs lost for Argentina, Brazil, Chile and
Uruguay combined [19]. DALYS lost due to CE were also found
to be similar to other conditions such as malaria, amoebiasis, and
leishmaniasis [24]. These infectious diseases are better monitored
than CE and thus their DALYs estimates are likely to better
capture the true impact of those diseases on the country. In the
case of CE, the absence of updated information on the frequency
of human CE hampers the calculation of this socio-economic
indicator. However, the number of DALYs estimated to be lost in
this study is very conservative since only surgical cases of CE were
evaluated.
The findings of the present economic evaluation, although
conservative, highlight the monetary losses caused by CE in the
Peru. Control programs could potentially prevent many of these
losses in a cost-effective manner. For example, a control program
implemented in the highly endemic region of La Rioja, Spain
based on a combination of owned dog deworming, stray dog
control, and safe ruminant carcass disposal resulted in a positive
cost/benefit ratio after 8 years. This ratio increased to 1.96 by the
conclusion of the 14-year program [25]. Control programs have
been previously implemented in Peru. For example, a pilot control
program was conducted in Peru during the 19709s which was later
abandoned due largely to political instability. However, the
program succeeded in reducing the number of infected dogs from
36% in 1975 to 1.6% in 1980 and the number of infected sheep
from 65% in 1976 to 37% in 1980 [2,26]. There is urgent need to
implement better surveillance systems to monitor the incidence/
prevalence of echinococcosis in humans and animals in Peru so
that they may be used as part of new control efforts for CE. In
summary, CE is an important but neglected zoonotic disease in
Peru which significantly affects the economy of the country.
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